Fresenius stock steadies near €47 as raised 2026 targets follow strong second quarter

Fresenius stock is trading just below €47 on Xetra after the healthcare group delivered better-than-expected second-quarter results and raised its guidance for 2026, giving investors a clearer earnings path despite only modest year-to-date gains.

Fresenius SE & Co. KGaA (ISIN DE0005785604) stock is changing hands around €47 on Xetra as of August 12, 2026, after the German healthcare group delivered stronger second-quarter results and raised its financial targets for 2026, according to recent market data and coverage.

Second-quarter beat and higher 2026 objectives

Recent analysis of Fresenius highlights that the company reported second-quarter results that were described as stronger than expected, with operating performance ahead of prior assumptions and an accompanying upgrade to management objectives for full-year 2026, as summarized by a detailed overview on Zonebourse.

Per that overview, Fresenius shares closed at €47.15 on Xetra in the most recent session, with a current real-time quote near €47.04 and a one-year objective price around €55.44 implied by the average of published targets, indicating upside of roughly 17.6 percent compared with the last closing price as of August 12, 2026.

Valuation, year-to-date performance and investor read-through

The same market snapshot shows Fresenius stock up about 0.99 percent since January 1, 2026, but still down approximately 3.8 to 4.0 percent over the past twelve months, signaling that the recent guidance hike has not yet translated into a broad rerating for the shares despite the fundamental improvement.

For investors, the quantified spread between the average objective price near €55.44 and the latest close at €47.15 as reported in mid-August 2026 underscores a market view that the company’s strengthened earnings profile and updated 2026 targets could justify a higher valuation if execution continues to track the revised plan.

Hospital and healthcare services business

Fresenius SE & Co. KGaA operates as a diversified healthcare group with major businesses in hospital operations, medical services and related products, including acute care and chronic therapy offerings that underpin its revenue base and long-term demand profile.

Fresenius stock price and market context

On Xetra, Fresenius stock most recently closed at €47.15, with real-time estimates around €47.04 as of August 12, 2026; the shares trade in euros and reflect a moderate gain year-to-date, while still sitting below the average published price objective of approximately €55.44 that many investors use as a medium-term reference point.

Fresenius stock at a glance

• Company: Fresenius SE & Co. KGaA
• ISIN: DE0005785604
• Ticker: FRE
• Exchange: Xetra
• Price (as of August 12, 2026, 1:08 p.m. CET): €47.15
• Market cap: value based on current Xetra quotation in mid-August 2026
• Sector / Industry: Health care - providers and services
• Index membership: DAX
• Next earnings date: not yet officially scheduled